Tuesday, 16 Oct 2018

You are here

Trends in Psoriatic Arthritis Treatment 2004-2015

Lee and colleagues from Brigham and Women's Hospital have analyzed the last decade of disease‐modifying antirheumatic drugs (DMARDs) use in patients with psoriatic arthritis (PsA) and found nearly 40% were treated with a bDMARD, along with a decreasing trend in complete DMARD discontinuations.

Data claims were derived from a large US commercial health plan, and identified PsA patients initiating DMARD therapy and changes in the DMARD regimen over the next 12‐month period.

Among the 9,222 PsA patients who initiated DMARD therapy, 57% started with a conventional synthetic DMARDs [csDMARDs] and 43% began with a biologic DMARD [bDMARD].

Those starting on bDMARDs tended to be younger (48 yrs vs 52 yrs) and had fewer comorbidities.

Methotrexate was the most frequently used csDMARD (80.6%) and etanercept (49.1%) was the most commonly prescribed bDMARD, followed by adalimumab (34.4%).

In the first 12‐months 20.1% of bDMARD initiators and 31.1% of csDMARD initiators had a change in their DMARD regimen.

Very few patients (5.3%) totally discontinued therapy, but the rates of discontinuation decreased over time (P < 0.001).

These data suggest that  the majority of PsA patients initiating DMARD therapy will remain on DMARD therapy for many years.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Apremilast Succeeds in Scalp Psoriasis

Celgene has announced results from the phase 3 STYLE study, showing apremilast yielding significant improvement in moderate-to-severe scalp psoriasis. STYLE is a phase 3, multicenter, randomized, placebo-controlled, double-blind study evaluating the efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis of the scalp. The study enrolled 303 people who were randomized 2:1 to receive apremilast 30 mg twice daily or placebo for the first 16 weeks.

Does Gender Make a Difference in Axial Spondyloarthritis

Males and females can both be affected by axial spondyloarthritis (axSpA). A recent study shows that while there are some differences and similarities, HLA-B27 and imaging are still pivotal elements for diagnosis of axSpA in both genders.

Complementary Therapies in Psoriasis

A systematic review in Archives of Dermatology suggests that among complementary and alternative medicine (CAM) therapies, the most effective are indigo naturalis, curcumin, dietary modification, meditation, and acupuncture.

It is estimated that  nearly half of patients with psoriasis report they use CAM, although their benefits are unclear in psoriasis.

Biologic Therapies Improve Work Outcomes in Spondyloarthritis

A study from the British Society for Rheumatology Biologics Register in Axial Spondyloarthritis (BSRBR-AS) shows that biologic use significantly improves work productivity and overall activity impairment.

 

The BSRBR-AS registry analyzed 577 participants who were employed;  28% were started on biological therapy .

BMS Tyk 2 Inhibitor Benefits Psoriasis

The NEJM reports that an oral selecive Tyrosine kinase 2 (TYK2) inhibitor of TYK2 was shown to be superior to placebo in a 12 week trial in patients with active psoriasis.